Heat Biologics, Inc. (HTBX) Reaches $2.21 After 3.00% Up Move; Profile of 3 Analysts Covering Pembina Pipeline (PBA)

June 13, 2018 - By reb123z

Pembina Pipeline Corporation (NYSE:PBA) Logo

Among 5 analysts covering Pembina Pipeline (NYSE:PBA), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Pembina Pipeline had 8 analyst reports since August 10, 2015 according to SRatingsIntel. GMP Securities upgraded the shares of PBA in report on Monday, November 7 to “Buy” rating. The rating was initiated by JP Morgan with “Overweight” on Thursday, October 13. The rating was downgraded by Credit Suisse on Monday, June 20 to “Neutral”. The firm earned “Outperform” rating on Friday, December 11 by Credit Suisse. As per Monday, August 10, the company rating was maintained by RBC Capital Markets. The firm has “Outperform” rating given on Monday, November 9 by RBC Capital Markets. The firm has “Sector Perform” rating given on Monday, July 18 by ational Bank Financial. See Pembina Pipeline Corporation (NYSE:PBA) latest ratings:

The stock of Heat Biologics, Inc. (NASDAQ:HTBX) is a huge mover today! The stock increased 4.25% or $0.0901 during the last trading session, reaching $2.2101. About 1.38M shares traded. Heat Biologics, Inc. (NASDAQ:HTBX) has declined 68.71% since June 13, 2017 and is downtrending. It has underperformed by 81.28% the S&P500. Some Historical HTBX News: ; 26/03/2018 – Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo Four-Week Dosing Schedule for Advanced; 27/03/2018 – U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTS BRISTOL-MYERS SQUIBB’S APPLICATION FOR OPDIVO (NIVOLUMAB) PLUS YERVOY (IPILIMUMAB) FOR PREVIOUSLY TREATED PATIENTS WITH MSI-H OR DMMR METASTATIC; 26/04/2018 – Bristol-Myers 1Q Opdivo Revenue $1.51 Billion; 15/05/2018 – X4 Pharmaceuticals Presents Clinical Data Demonstrating Combinability of X4P-001-IO and Opdivo® (nivolumab) in Patients with; 26/04/2018 – Opdivo Drives Bristol-Myers Growth — Earnings Review; 06/03/2018 – BRISTOL-MYERS SQUIBB – OPDIVO ALSO WAS APPROVED FOR A SHORTER 30-MINUTE INFUSION ACROSS ALL APPROVED INDICATIONS; 16/04/2018 – BRISTOL-MYERS OPDIVO CHECKMATE 141 SHOWED SUSTAINED OS; 16/04/2018 – BRISTOL-MYERS SQUIBB CO – IN STUDY, TWO-YEAR SURVIVAL RATE FOR OPDIVO WAS 16.9% VERSUS 6.0% FOR STANDARD CHEMOTHERAPY; 26/03/2018 – BRISTOL-MYERS SQUIBB CO – CHMP RECOMMENDATION OF OPDIVO WILL NOW BE REVIEWED BY EUROPEAN COMMISSION; 16/04/2018 – In CheckMate -141, Opdivo (nivolumab) Demonstrated Sustained Overall Survival (OS) Advantage over Standard of Care in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)The move comes after 6 months positive chart setup for the $45.99 million company. It was reported on Jun, 13 by Barchart.com. We have $2.28 PT which if reached, will make NASDAQ:HTBX worth $1.38 million more.

Pembina Pipeline Corporation provides transportation and midstream services for the energy industry in North America. The company has market cap of $17.40 billion. It operates through four divisions: Conventional Pipelines, Oil Sands & Heavy Oil, Gas Services, and Midstream. It has a 24.13 P/E ratio. The Conventional Pipelines segment operates approximately 10,000 kilometers of pipeline network that transports hydrocarbon products and extends across Alberta and parts of British Columbia, Saskatchewan, and North Dakota.

More important recent Pembina Pipeline Corporation (NYSE:PBA) news were published by: Streetinsider.com which released: “Pembina Pipeline (PBA) Updates 2018 Guidance, Will Host Annual Investor Day” on May 29, 2018, also Finance.Yahoo.com published article titled: “3 Stocks That Pay You Each Month”, Fool.com published: “China is Using This, Not Renewable Energy, to Replace Coal” on June 04, 2018. More interesting news about Pembina Pipeline Corporation (NYSE:PBA) was released by: Seekingalpha.com and their article: “Bright future seen for US LNG, ethanol sellers on potential China deals” with publication date: May 22, 2018.

The stock increased 0.67% or $0.23 during the last trading session, reaching $34.63. About 172,999 shares traded. Pembina Pipeline Corporation (NYSE:PBA) has risen 2.84% since June 13, 2017 and is uptrending. It has underperformed by 9.73% the S&P500. Some Historical PBA News: ; 09/04/2018 – PEMBINA PIPELINE REPORTS CHANGES TO REPORTING SEGMENTS; 22/03/2018 – PEMBINA PIPELINE CORP – OFFERING WILL ALSO CONSIST OF $300 MLN IN SENIOR UNSECURED MEDIUM-TERM NOTES, SERIES 11; 22/03/2018 – PEMBINA PIPELINE CORPORATION ANNOUNCES $700 MILLION PUBLIC NOTE OFFERING; 09/03/2018 PEMBINA PIPELINE CORPORATION DECLARES COMMON SHARE DIVIDEND AND ANNOUNCES CLOSING OF TERM LOAN; 03/05/2018 – PEMBINA PIPELINE CORP – APPROVED A 5.6 PCT INCREASE IN ITS MONTHLY COMMON SHARE DIVIDEND RATE, FROM $0.18 PER COMMON SHARE TO $0.19 PER COMMON SHARE; 27/03/2018 – Enbridge Income Fund, Pembina Pipeline Corp Each Owns 50% of Alliance Pipeline; 03/05/2018 – PEMBINA PIPELINE – ABOUT $280 MLN PHASE Vl EXPANSION IS ANTICIPATED TO BE IN SERVICE IN EARLY 2020, SUBJECT TO ENVIRONMENTAL AND REGULATORY APPROVAL; 29/05/2018 – Pembina Pipeline Now Sees FY18 View to Ebitda C$2.65B-Ebitda C$2.75; 03/05/2018 – PEMBINA PIPELINE – THE $280 MLN PHASE Vl EXPANSION IS ANTICIPATED TO BE IN SERVICE IN EARLY 2020, SUBJECT TO ENVIRONMENTAL AND REGULATORY APPROVAL; 28/03/2018 – PEMBINA PIPELINE CORPORATION ANNOUNCES ALLIANCE PIPELINE OPEN SEASON

Heat Biologics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel allogeneic therapies for a range of cancers and infectious diseases in the United States. The company has market cap of $45.99 million. The firm develops its products based on T cell-stimulating platform technologies, including immune pan-antigen cytotoxic therapy, a platform technology designed to educate and stimulate the immune system against specific disease targets, such as cancer cells; and combination pan-antigen cytotoxic therapy, a platform technology that combines a pan-antigen T cell activating vaccine and a T cell co-stimulator in a single product. It currently has negative earnings. The Company’s product candidates include HS-110 that is in Phase 2 clinical trials for the treatment of non-small cell lung cancer; and HS-410, which is in Phase 2 clinical trials for the treatment of non-muscle invasive bladder cancer.

Another recent and important Heat Biologics, Inc. (NASDAQ:HTBX) news was published by Benzinga.com which published an article titled: “42 Biggest Movers From Yesterday” on June 13, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.